Next-Generation Beneficial Microbes: The Case of Akkermansia muciniphila.
Next-Generation Beneficial Microbes: The Case of Akkermansia muciniphila.
复制标题
DOI：
10.3389/fmicb.2017.01765
复制
发表时间：
2017
影响因子：
5.2
通讯作者：
de Vos WM
中科院分区：
文献类型：
--
作者：
Cani PD;de Vos WM
与肥胖相关的代谢紊乱和心脏代谢紊乱是世界范围内的流行病。在不同的环境因素中，肠道微生物群现在被认为是干扰能量代谢和宿主对几种非传染性疾病易感性的关键因素。在已经鉴定的下一代有益微生物中，Akkermansia muciniphila是一个有希望的候选者。的确，A.嗜粘蛋白与肥胖、糖尿病、心脏代谢疾病和低度炎症负相关。除了观察到的众多相关性外，大量证据已经证明了这种细菌在各种临床前模型中的因果有益影响。将这些令人兴奋的观察结果翻译给人类将是下一个逻辑步骤，现在看来，阻止使用A。已经克服了人类中的嗜粘蛋白体给药。此外，一些证据表明，巴氏杀菌的A。嗜粘蛋白体不仅增加了其稳定性，而且更重要的是增加了其功效。这是A的有力位置。在开发具有有益效果的新型食品或药物补充剂的下一代候选人中，muciniphila处于最前沿。最后，一种存在于A.被称为Amuc_1100的嗜粘蛋白菌可能是未来药物开发的强有力候选物。总之，由于植物及其相关知识，即生药学，在上个世纪一直是设计药物的来源，我们建议微生物和微生物组学，或我们肠道微生物组的知识，可以成为未来疗法的新来源。
Metabolic disorders associated with obesity and cardiometabolic disorders are worldwide epidemic. Among the different environmental factors, the gut microbiota is now considered as a key player interfering with energy metabolism and host susceptibility to several non-communicable diseases. Among the next-generation beneficial microbes that have been identified, Akkermansia muciniphila is a promising candidate. Indeed, A. muciniphila is inversely associated with obesity, diabetes, cardiometabolic diseases and low-grade inflammation. Besides the numerous correlations observed, a large body of evidence has demonstrated the causal beneficial impact of this bacterium in a variety of preclinical models. Translating these exciting observations to human would be the next logic step and it now appears that several obstacles that would prevent the use of A. muciniphila administration in humans have been overcome. Moreover, several lines of evidence indicate that pasteurization of A. muciniphila not only increases its stability but more importantly increases its efficacy. This strongly positions A. muciniphila in the forefront of next-generation candidates for developing novel food or pharma supplements with beneficial effects. Finally, a specific protein present on the outer membrane of A. muciniphila, termed Amuc_1100, could be strong candidate for future drug development. In conclusion, as plants and its related knowledge, known as pharmacognosy, have been the source for designing drugs over the last century, we propose that microbes and microbiomegnosy, or knowledge of our gut microbiome, can become a novel source of future therapies.
登录
查看更多内容
影响因子：
7.7
作者：
Cani, Patrice D.;Amar, Jacques;Burcelin, Remy
通讯作者：
Burcelin, Remy
影响因子：
11.1
作者：
Amar, Jacques;Chabo, Chantal;Waget, Aurelie;Klopp, Pascale;Vachoux, Christelle;Bermudez-Humaran, Luis G.;Smirnova, Natalia;Berge, Mathieu;Sulpice, Thierry;Lahtinen, Sampo;Ouwehand, Arthur;Langella, Philippe;Rautonen, Nina;Sansonetti, Philippe J.;Burcelin, Remy
通讯作者：
Burcelin, Remy
DOI：
10.1038/ismej.2014.45
发表时间：
2014-10
期刊：
The ISME journal
影响因子：
--
作者：
通讯作者：
--
影响因子：
24.5
作者：
Cani PD;Possemiers S;Van de Wiele T;Guiot Y;Everard A;Rottier O;Geurts L;Naslain D;Neyrinck A;Lambert DM;Muccioli GG;Delzenne NM
通讯作者：
Delzenne NM
影响因子：
5.2
作者：
Derrien M;Van Baarlen P;Hooiveld G;Norin E;Müller M;de Vos WM
通讯作者：
de Vos WM